Non-coding RNAs (ncRNAs) have a significant regulatory role in the pathogenesis of skin cancer, despite the fact that protein-coding genes have generally been the focus of research efforts in the field. We comment on the actions of long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) in the current review with an eye toward potential therapeutic treatments. LncRNAs are remarkably adaptable, acting as scaffolding, guides, or decoys to modify key signaling pathways (i.e., the Wnt/β-catenin pathway) and gene expression. As post-transcriptional gatekeepers, miRNAs control gene expression by attaching to messenger RNAs and causing their degradation or suppression during translation. Cell cycle regulation, cellular differentiation, and immunological responses are all affected by the dysregulation of miRNAs observed in skin cancer. NcRNAs also show promise as diagnostic biomarkers and prognostic indicators. Unraveling the complexity of the regulatory networks governed by ncRNAs in skin cancer offers unprecedented opportunities for groundbreaking targeted therapies, revolutionizing the landscape of dermatologic care.

Characterized by pruritic, scaly plaques, psoriasis is an immune-mediated chronic cutaneous condition associated with a negative impact on quality of life. In addition, psoriatic patients exhibit a greater incidence of anxiety and depression compared to the general population. The relationship between psoriasis and mental health has been shown to be bidirectional with disease activity worsening psychological burden, and psychological burden conversely impacting disease activity. While few studies to our knowledge precisely delineate the proportion of psoriatic patients with untreated mental health concerns, literature suggests many patients are not receiving optimal or timely mental health treatment. As such, researchers have explored various psychotherapeutic interventions to increase the quality of life among patients, including traditional psychotherapy, cognitive behavioral therapy, and various alternative modalities. This chapter seeks to discuss the psychological burden of psoriasis, both in relation to psychological comorbidity and overall quality of life. In addition, this chapter seeks to review evidence for psychological interventions for patients with psoriasis. A greater understanding of the mental health outcomes of psoriatic patients and psychological interventions may better equip clinicians with the necessary tools to treat psoriatic patients holistically, addressing both the physical and mental burden of the disease.